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Magnetic Resonance Guided High-Intensity Focused
Ultrasound Mediated Hyperthermia Improves the Intratumoral
Distribution of Temperature-Sensitive Liposomal Doxorubicin
Mariska de Smet, MSc,* Nicole M. Hijnen, MSc,* Sander Langereis, PhD,Þ Aaldert Elevelt, MSc,Þ
Edwin Heijman, PhD,Þ Ludwig Dubois, PhD,þ Philippe Lambin, MD, PhD,þ and Holger Grüll, PhD*Þ
Objectives: The aim of this study was to investigate the intratumoral distri-
bution of a temperature-sensitive liposomal carrier and its encapsulated com-
pounds, doxorubicin, and a magnetic resonance (MR) imaging contrast agent
after high-intensity focused ultrasound (HIFU)Ymediated hyperthermia-
induced local drug release.
Materials and Methods: 111In-labeled temperature-sensitive liposomes en-
capsulating doxorubicin and [Gd(HPDO3A) (H2O)] were injected intravenously
in the tail vein of rats (n = 12) bearing a subcutaneous rhabdomyosarcoma
tumor on the hind leg. Immediately after the injection, local tumor hyperthermia
(2  15 minutes) was applied using a clinical 3 T MR-HIFU system. Release
of [Gd(HPDO3A)(H2O)] was studied in vivo by measuring the longitudinal re-
laxation rate R1 with MR imaging. The presence of the liposomal carriers and
the intratumoral distribution of doxorubicin were imaged ex vivo with autoradi-
ography and fluorescence microscopy, respectively, for 2 different time points
after injection (90 minutes and 48 hours).
Results: In hyperthermia-treated tumors, radiolabeled liposomes were dis-
tributed more homogeneously across the tumor than in the control tumors
(coefficient of variationhyp, 90 min = 0.7 T 0.2; coefficient of variationcntrl, 90 min =
1.1 T 0.2). At 48 hours after injection, the liposomal accumulation in the
tumor was enhanced in the hyperthermia group in comparison with the
controls. A change in R1 was observed in the HIFU-treated tumors, sug-
gesting release of the contrast agent. Fluorescence images showed perivas-
cular doxorubicin in control tumors, whereas in the HIFU-treated tumors,
the delivered drug was spread over a much larger area and also taken up by
tumor cells at a larger distance from blood vessels.
Conclusions: Treatment with HIFU hyperthermia not only improved the im-
mediate drug delivery, bioavailability, and intratumoral distribution but also
enhanced liposomal accumulation over time. The sum of these effects may
have a significant contribution to the therapeutic outcome.
Key Words: intratumoral distribution, temperature-sensitive liposomes, high-
intensity focused ultrasound, hyperthermia, doxorubicin
(Invest Radiol 2013;48: 395Y405)
Magnetic resonance (MR)Yguided high-intensity focused ultra-sound (HIFU) is an emerging noninvasive technology for local
thermal therapies in oncology. Magnetic resonance imaging (MRI)
provides excellent soft tissue contrast for therapy planning and spa-
tial guidance.1,2 In addition, MR allows dynamic mapping of the
HIFU-induced temperature change, providing direct feedback to the
ultrasound control unit.1Y3 The latter is a prerequisite for accurate
HIFU-induced mild hyperthermia (HIFU-HT) (40-CY42-C) of tumors
over a prolonged period of time.4Y6 Local mild hyperthermia of tumor
tissue in conjunction with chemotherapy and radiotherapy has demon-
strated a significant enhancement in the tumor treatment efficacy.7Y9
The observed synergistic effects are manifold and may originate from
an increased blood flow, an enhanced permeability of the tumor (mi-
cro)vasculature, and enhanced extravasation of drugs, the expression
of heat shock proteins, inhibition of DNA repair, and the stimulation of
immune responses.10Y16 Penetration of small molecular chemothera-
peutic drugs to cells at a larger distance from blood vessels is benefi-
cial for the treatment of solid tumors,17Y20 which potentially could
benefit from hyperthermia. Furthermore, liposomal drug formulations
benefit from hyperthermia, thanks to an increased extravasation from
the vascular compartment into the interstitial space.13,21 Besides
these synergistic effects in systemic chemotherapy, local hyperther-
mia has been used to trigger the release of chemotherapeutic drugs
from temperature-sensitive liposomes (TSLs).22,23 Previous studies
have demonstrated that hyperthermia-mediated drug delivery from
TSLs resulted in increased drug concentrations in the tumor com-
pared with levels achieved with systemic drug administration or nonY
temperature-sensitive liposomal drug formulations.24Y29 The triggered
release of drugs from the responsive liposomal formulation makes
the drug bioavailable to tumor cells as opposed to the limited bio-
availability of drugs that are encapsulated in non-TSLs.30,31 Recently,
Staruch et al32 demonstrated that the delivery of doxorubicin from
TSLs induced by MR-HIFU results in enhanced intracellular uptake
of bioavailable drug in heated tumors. Similar results were obtained
by Ranjan et al,26 showing an increased doxorubicin uptake in the tu-
mor periphery as well as in the tumor core, suggesting an improved
intratumoral distribution of the drug. After the application of hyper-
thermia for 30 minutes, more than 60% of the injected dox-loaded
TSLs was still present in the blood circulation. Their contribution to
the overall drug uptake in the tumor over longer times remains un-
clear, as the effects of HIFU-mediated hyperthermia might show a
considerable reminiscence leading to an additional uptake of drug-
filled liposomes via the enhanced permeability and retention effect.
Noninvasive MRI and quantification of the drug delivery
process have been demonstrated using paramagnetic TSLs coencap-
sulating drugs and MRI contrast agents (CAs).33Y37 At hyperthermia,
the MRI CA is released from the aqueous lumen of the TSL, resulting
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in a change in the longitudinal relaxation rate ($R1 = 1/$T1),
which can be used to probe the drug release.38 Temperature-sensitive
liposomes loaded with doxorubicin and [Gd(HPDO3A)(H2O)]
have shown a good correlation between the MR contrast enhance-
ment and the uptake of doxorubicin in 9L glioma tumors upon
MR-HIFUYinduced release.36
In the work presented here, we designed 111In-labeled TSLs
encapsulating doxorubicin and [Gd(HPDO3A)(H2O)] for hyperthermia-
triggered drug delivery under MR image guidance (Fig. 1). The ef-
fect of local MR-HIFUYmediated hyperthermia on the intratumoral
distribution of the drug and the liposomal carrier was studied at
90 minutes and 48 hours after intravenous injection. At 90 minutes,
a significant fraction of the TSLs is still circulating in the blood, and
consequently, the effect of heat-triggered release is measured against
passive extravasation of drug-filled liposomes. After 48 hours, the
combined effect of heat-triggered release, possible hyperthermia rem-




hydrogenated-L->-phosphatidylcholine (HSPC) were kindly provided
by Lipoid (Ludwigshafen, Germany). 1,2-Dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DPPE-
PEG2000) and cholesterol were purchased from Avanti Polar Lipids
(Alabaster, AL). 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA)-1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)
was synthesized according to the procedure described by Hak et al.39
Doxorubicin hydrochloride was purchased from AvaChem Scientific
(San Antonio, TX). [Gd(HPDO3A)(H2O)] (ProHance) was obtained
from Bracco Diagnostics (Milan, Italy).
Preparation, Characterization, and Radiolabeling
of TSLs
Temperature-sensitive liposomes were prepared and character-
ized in a similar fashion as previously described.36 DPPC:HSPC:Chol:
DPPE-PEG2000:DOTA-DSPE (50:25:15:3:1 molar ratio) were dis-
solved in a solution of chloroform-methanol (4:1 vol/vol). The organic
solvents were removed in vacuo until a thin lipid film was formed,
which was further dried overnight under nitrogen flow. The lipid film
was hydrated at 60-C in 120 mM (NH4)2SO4 buffer at pH 5.4 con-
taining 250 mM [Gd(HPDO3A)(H2O)]. The suspension was ex-
truded at 60-C successively through a polycarbonate filter of 200 nm
(2 times) and 100 nm (6 times). Subsequently, the extraliposomal
buffer was replaced by HEPES-buffered saline (HBS) (20 mM HEPES
and 137 mM NaCl at pH 7.4) by gel filtration through a PD-10 col-
umn. Doxorubicin in HBS (5 mg/mL) was added to the TSLs at a
phospholipid-to-doxorubicin molar ratio of 17.5:1 and the TSLs were
incubated at 37-C overnight. Finally, the TSLs were passed through
a 0.22-Hm filter and a second PD-10 column to remove any nonen-
capsulated doxorubicin. The liposomes were concentrated using an
Amicon Ultra-4 Centrifugal Filter Unit (100 kDa molecular weight
cut off; Millipore).
The hydrodynamic radius of the TSLs was determined in HBS
using dynamic light scattering (ALV/CGS-3 Compact Goniometer
System; ALV-GmbH, Langen, Germany). The melting phase transi-
tion temperature (Tm) of the liposomal bilayer was determined with
differential scanning calorimetry (Q2000; TA Instruments, USA)
during heating with 5 K/min from 20-C to 60-C. The doxorubicin
concentration was determined with a spectrophotometer (Perkin
Elmer LS55, Lex = 485 nm and Lem = 590 nm) in isopropyl alcohol/
H2O (1:1 vol/vol). The phospholipid concentration was measured by
phosphate determination according to Rouser et al.40 The gadolinium
concentration was determined by inductively coupled plasma-mass
spectrometry.
FIGURE 1. 111In-labeled TSLs encapsulating doxorubicin and [Gd(HPDO3A)(H2O)]. The drug and MRI CA are released from the
aqueous lumen at temperatures approaching the melting phase transition temperature of the lipid bilayer.
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Before injection, the TSLs were radiolabeled by overnight
incubation at 30-C with 111InCl3 in 95 mM ammonium acetate buffer
at pH 4.5. The radiolabeling yield was tested with radio-thin layer
chromatography (running buffer: 200 mM EDTA in saline) before
and after 10 minutes of incubation with 0.1 mM diethylene triamine
pentaacetic acid. Subsequently, the sample was passed through a
Zeba Desalt Spin column (7 kDa) preequilibrated with HBS (pH 7.4),
resulting in 111In-labeled TSLs with a radiolabeling yield of greater
than 95%.
Animal Model
All preclinical studies were approved by the animal welfare
committee of Maastricht University (the Netherlands). The mainte-
nance and care of the experimental animals were in compliance with
the guidelines set by the institutional animal care committee, accre-
dited by the National Department of Health. Syngeneic R1 rhabdo-
myosarcoma tumors were established on the hind leg of female Wag/
Rij rats (n = 12) (age 5Y7 weeks; Charles River) by subcutaneous
implantation under anesthesia with pieces of donor tumor tissue
(È1 mm3).41 Tumor sizes were determined by measuring the length (l),
width (w), and depth (d) using a caliper, and the tumor volume was
calculated by 0.5  l  w  d. Animal studies were performed with
tumor volumes between 300 and 1000 mm3, typically 14 to 20 days
after tumor implantation.
MR-HIFU Protocol
Local hyperthermia of the tumor was performed by MR-HIFU
heating in a similar manner as described previously.36,42 All animals
received Rimadyl (carprofen, 4 mg/kg body weight) as a precautional
pain suppressor before the treatment. Ultrasound gel (Aquasonic 100;
Parker Laboratories, Fairfield, NJ) was applied onto the shaven leg
and tumor. The animal was placed into a dedicated multichannel
small animal MR receiver coil that was used as add-on to a clinical
MR-HIFU platform (Philips Sonalleve, Vantaa, Finland).42 The res-
piration rate and body temperature of the animal were monitored
continuously. The MR-HIFU platform was integrated into a 3 T hu-
man MR scanner (Philips Achieva, Best, the Netherlands). Subse-
quently, the treatment was planned on T2-weighted MR images
acquired with a turbo spin echo scan (turbo spin echo factor, 7;
repetition time [TR]/echo time [TE], 7644/50 milliseconds; field of
view [FOV], 40  60  50 mm3; voxel size, 0.5  0.5  0.6 mm3;
slices, 20; saturation bands, 2; acquisition time, 1.39 minutes). An
ellipsoidal-shaped HIFU treatment cell (diameter , 4 mm, length ,
10 mm) was positioned in the center of the tumor. Several low-power
test sonications (continuous wave ultrasound; acoustic frequency,
1.44 MHz; acoustic power, 5-10 W; duration, 20 seconds; typical
temperature elevation , 1-CY2-C) were performed before therapeutic
sonication to correct for possible focus point aberration. During
sonication, proton resonance frequency shiftYbased MR thermometry
was used to monitor the temperature change in the target region by
continuous acquisition of 1 slice perpendicular and 1 slice parallel to
the beam axis, all centered on the target area (RF spoiled gradient
echo with EPI readout; flip angle, 19.5-; TR/TE, 52/19.5 milli-
seconds; EPI factor, 7; SENSE factor, 1.8; FOV, 250  250 mm;
matrix, 176  169; slice thickness, 4 mm; number of averages, 4; fat
suppression, SPIR; dynamic scan time, 4.8 seconds). For prolonged
hyperthermia (acoustic power, 10 W), the heating was controlled
using a binary feedback control algorithm.5,42 A zero-order phase
correction was performed for baseline drift correction by subtracting
the average phase in a reference region from the MR-acquired phase
image, before the calculation of the temperature image.
Maps of the longitudinal relaxation time (T1) were acquired
before and after the two 15-minute hyperthermia treatments, us-
ing a single-slice Look-Locker sequence43 (flip angle, 10-; TR/TE,
9.0/3.4 milliseconds; interval time, 100 milliseconds; time of inversion
repetition, 6 seconds; EPI factor, 5; FOV, 50 69mm; matrix, 64 65;
half scan, 80%; slice thickness, 2 mm; number of averages, 2;
fat suppression, SPIR; acquisition time, 2 minutes 36 seconds). The
effective T1 (T1*) was calculated from the signal recovery on a voxel-
by-voxel basis using an in-house created IDL-based software tool
(IDL version 6.3; RSI, Broomfield, CO). Further data processing
was performed in MATLAB (R2010a; MathWorks, Natick, MA),
in which the longitudinal relaxation rate R1 was calculated from
the effective R1* (R1* = 1/T1*, R1 = R1* + ln(cos(>))/TR, with > =
10- and TR = 100 milliseconds)44 on a voxel-by-voxel basis.
Once the HIFU treatment was planned and coregistered, 111In-
labeled TSLs (20 T 5 MBq 111In, 0.50 T 0.03 mL) were injected via a
tail vein catheter at a dose of 5 mg/kg doxorubicin. Immediately after
the injection, the HIFU-induced hyperthermia treatment was started.
In the control group, animals received the same handling as the
HIFU-treated animals, except for the actual heating. Rats were killed
90 minutes or 48 hours after TSL injection, after which the tumor was
dissected. The treatment protocol is shown schematically in Figure 2.
The group sizes were n = 3 for hyp 90 min, n = 4 for control 90 min,
n = 3 for hyp 48 h and n = 2 for control 48 h.
Autoradiography
The activity in the entire dissected tumor was measured using
a dose calibrator (VDC-405; Veenstra Instruments). Subsequently,
tumor slices of 2-mm thickness were cut from the middle of the tu-
mor using a stainless steel tissue matrix (Ted Pella Inc). Tissue dye
was used to mark the tumor, to select the slice corresponding to the
middle of the HIFU treatment cell. After weighing, the slices were
exposed to a photostimulable phosphor plate for a time varying from
4 hours to 2 days, depending on the amount of radioactivity in the
tumor slice. The exposed plates were scanned using a phosphor im-
ager (FLA-7000; Fujifilm). To quantify the homogeneity of the TSL
distribution, the coefficient of variation (CV) was calculated of the
histogram of pixel intensities from the autoradiographic images.
Therefore, regions of interest were manually drawn around the tu-
mor sections (ImageJ; NIH, Bethesda, MD). The CVs between the
hyperthermia and control groups were compared statistically using a
2-sided t test (Statgraphics Centurion, version 16.0.05).
Subsequently, the radioactivity of the tumor slices was quan-
tified using F-counting (Wizard 3W; Perkin Elmer). Known volumes
of the injected TSLs were counted to serve as reference. The decay-
corrected radioactivity in the slices was expressed as a percentage of
the injected dose per gram tissue (%ID/g).
FIGURE 2. Timelines for the MR-HIFU group and the control
experiment (without MR-HIFU). Animals were euthanized either
at 1.5 or 48 hours after the administration of the TSLs.
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Histology
The tumor parts that were not used for autoradiography were
snap frozen in 2-methyl butane and stored at j20-C before histo-
logical analysis. The frozen tissue was cut into 6-Hm slices. Fluo-
rescence images of the doxorubicin distribution were acquired with a
fluorescence microscope (DM6000B, DFC310FX camera; Leica)
equipped with a custom-made doxorubicin filter set (excitation, 480/
40 nm; emission, 600/60 nm; dichroic, 505lp). Subsequently, the tis-
sue slides were stained with CD31 and DAPI to mark the endothelial
cells and cell nuclei, respectively. After fixation with ice-cold acetone
(5 minutes at j20-C), the slides were air-dried and washed in PBS.
A blocking step was performed with 20% goat serum in phosphate
buffered saline (PBS) containing 1% bovine serum albumin (BSA)
for 15 minutes to minimize nonspecific staining. Primary incuba-
tion of mouse monoclonal antirat CD31 antibody (BD Pharmingen)
was performed at a dilution of 1:50 in PBS containing 1% BSA for
2 hours at room temperature. Secondary incubation was performed
using antimouse immunoglobulin GYFITC antibody (F5387; Sigma)
(1:100 in PBS containing 1% (BSA) and 5% goat serum) for 1 hour
at room temperature. Finally, the sections were incubated with DAPI
(Invitrogen, Molecular Probes) for 10 minutes at room temperature
and mounted (Fluoromount F4680; Sigma). Between every step, the
sections were washed with PBS. Sections were examined with fluo-
rescence microscopy (filters L5 [FITC] and R/G/B [DAPI]), and the
different color channels were merged (ImageJ, http://rsbweb.nih.gov).
For anatomical analysis, tissue slides were air-dried briefly at room
temperature and stained with hematoxylin and eosin. Cell viability was
analyzed after nicotinamide adenine dinucleotide (NADH)-diaphorase
staining. For the latter, tissue slides were incubated at 37-C for 1 hour
in a Gomori-Tris-HCl buffer (pH 7.4, 10 mL) containing A-NAD re-
duced disodium salt hydrate (N8129; 10 mg; Sigma-Aldrich, St Louis,
MO) and nitro blue tetrazolium (N5514; 10 mg; Sigma-Aldrich).




Temperature-sensitive liposomes encapsulating doxorubicin
and [Gd(HPDO3A)(H2O)] with an average hydrodynamic diameter
of 121.8 nm (polydispersity index G0.1) have been prepared. The
melting phase transition temperature (Tm), defined as the onset of the
phase transition peak in the differential scanning calorimetry ther-
mogram, was 42.4-C T 0.1-C. The phosphorus, gadolinium, and
doxorubicin concentrations of the TSL solution were 64.9 T 1.8 mM,
15.6 T 0.8 mM, and 3.3 T 0.1 mM, respectively. The incorporation of
1 mol% DOTA-DSPE in the phospholipid bilayer did not affect the
stability of the liposomes at 37-C, nor the doxorubicin release at
42-C (Supplemental Figure S1, Supplemental Digital Content 1,
http://links.lww.com/RLI/A74). Before injection, the DOTA-func-
tionalized TSLs were labeled with 111In (41 T 10 MBq/mL), resulting
in 111In-labeled TSLs with a radiolabeling yield of greater than 95%.
MR-HIFU Treatment
The HIFU-mediated hyperthermia of the tumor was applied
immediately after the administration of TSLs. The therapy planning
and the temperature maps of the MR-HIFU treatment over time are
shown in Figure 3. Although the HIFU treatment cell volume of
approximately 85 mm3 was smaller than the tumor volume of ap-
proximately 500 mm3, mild hyperthermia of most of the tumor vol-
ume was achieved 2 minutes after the onset of HIFU sonication due
to heat diffusion (Fig. 3). Furthermore, gradual warming of the
muscle surrounding the tumor was observed over time, with some
areas reaching similar temperatures as the center of the tumor. During
the hyperthermia treatments (2 times 15 minutes), the heating was
monitored and controlled using a binary feedback control algorithm,
obtaining an average temperature in the treatment cell of 41-C T 2-C.
Based on previous in vitro measurements, the TSLs are expected to
show quantitative release of the encapsulated doxorubicin and
[Gd(HPDO3A)(H2O)] within a few minutes at these temperatures.38
Maps of the longitudinal relaxation rate (R1) were acquired
before TSL injection and directly after the hyperthermia treatments to
probe the release of the MRI CA from the liposomal carrier (Fig. 4).
The combination of TSLs and HIFU-induced hyperthermia resulted
in an increase in tumor R1 ($R1,tumor 15 min = 0.15 T 0.10, P = 0.022,
2-sided paired t test), whereas the R1 values of the adjacent muscle
remained constant ($R1,muscle 15 min = 0.02 T 0.07, P = 0.628, 2-sided
paired t test). The second hyperthermia treatment did not result in a
further R1 increase ($R1,tumor 30 min = 0.15 T 0.11, P = 0.934, 2-sided
paired t test). Control experiments in rats with TSLs without HIFU
treatment showed similar R1 changes in the tumor as in the sur-
rounding muscle upon injection of the TSLs, suggesting that the li-
posomal content was not actively released from the TSLs in the
unheated tumors. At the end of the protocol (90 minutes or 48 hours
after TSL injection), the rats were killed. The tumors were dissected
for further analysis using a dose calibrator, autoradiography, and
histology.
Autoradiography
The intratumoral distribution of the 111In-labeled TSLs
was investigated using autoradiography. Figure 5 shows 1 represen-
tative autoradiography image per group. The autoradiography im-
ages of all investigated tumor slices, as well as the images scaled
to the same %ID/g, can be found in the Supplementary Informa-
tion (Supplemental Figure S2, Supplemental Digital Content 2,
http://links.lww.com/RLI/A75). At 90 minutes after injection, the
high TSL concentration in the blood (950% of the injected dose36)
contributed, to a large extent, to the activity observed on autoradiog-
raphy. In control tumors, most activity was present in major blood
vessels, the tumor rim, and the supporting tissue layer between the
skin and the tumor (Fig. 5 and Supplemental Figure S2, Supple-
mental Digital Content 2, http://links.lww.com/RLI/A75). Table 1
shows the amount of radioactivity in the tumor slices as well as
in the whole tumor. At 90 minutes after injection, the 111In up-
take was not increased because of hyperthermia treatment in com-
parison with the controls (t test whole tumor90 min hyperthermia
vs control: P = 0.684). However, the distribution of radioactivity
over the tumor was different, as areas in the core of the heated tumors
showed higher uptake (Fig. 5 and Supplemental Figure S1, Sup-
plemental Digital Content 1, http://links.lww.com/RLI/A74). In the
hyperthermia-treated tumors, the CVof the activity distribution was
significantly lower than for the control tumors (t test, P = 0.002),
suggesting a more homogeneous activity distribution over the tu-
mors after HIFU hyperthermia treatment. This effect was maintained
48 hours after injection (t test, P = 0.037; Supplemental Figure S2,
Supplemental Digital Content 2, http://links.lww.com/RLI/A75).
After 48 hours, also an activity increase was observed in the hy-
perthermia group (see Table 1), suggesting that enhanced liposome
accumulation and extravasation after the heating have finished.
Histology
The intratumoral distribution of doxorubicin was examined by
fluorescence microscopy. In control tumors (t = 90 minutes), doxo-
rubicin uptake was visible only in the endothelial cells. For the HIFU-
treated tumors, the delivered drug was spread over a larger area
(Fig. 6). Furthermore, the doxorubicin was colocalized with tumor
cell nuclei, indicating cellular uptake even at relatively large dis-
tances (,50 Km) from blood vessels. On DAPI (cell nuclei), CD31
(endothelial cell), and hematoxylin and eosin staining, the hyper-
thermia-treated tumor appeared similar as the control tumor tissue,
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showing a tight packing of cell nuclei and a large amount of well-
structured blood vessels distributed over the entire tumor. In both the
HIFU-treated and control groups, NADH-diaphorase staining for cell
viability showed viable tumor tissue 90 minutes after TSL injection,
indicating that there was no instant effect of the therapy on the
cell viability.
After 48 hours, cellular uptake of doxorubicin was observed in
the control tumors, however to a smaller extent compared with the
hyperthermia-treated ones (Fig. 7). In the hyperthermia group, areas
that showed a high liposome accumulation on autoradiography also
showed high fluorescence on the fluorescence microscopy (Fig. 8).
Interestingly, these areas were congruent with the areas that showed no
cell viability on NADH-diaphorase staining. Although a contribution
of autofluorescence of necrotic tissue to the signal cannot be fully ex-
cluded, the high fluorescent signal observed in this area most likely
results from a high doxorubicin uptake. Outside the high-intensity area,
the doxorubicin signal was comparable with that in control tumors and
viable according to the NADH-diaphorase staining.
DISCUSSION
In our work, the effect of HIFU-mediated hyperthermia on
the intratumoral distribution of TSLs, as well as for the released
FIGURE 3. MR-HIFU therapy planning and temperature maps. On the top left, anatomical images are shown with an overlay of the
planned treatment volume (green ellipsoid). The red contours indicate the tumor area. M indicates the leg muscle. Temperature maps
are shown perpendicular to the ultrasound beam path (left images, coronal) and parallel to the beam path (right images, transversal)
over time (t) during hyperthermia treatment. On the top right, the mean temperature of the treatment cell is plotted against time.
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doxorubicin and MRI CA, has been investigated at different time
points after injection. The localization of the TSLs and the cellular
uptake of doxorubicin were studied using autoradiography and fluo-
rescent microscopy, respectively. Moreover, the in situ release of doxo-
rubicin from the TSLs was probed with MRI by measuring the change
in relaxation times induced by the corelease of [Gd(HPDO3A)(H2O)].
Radiographic images of the control tumors showed highest
radioactivity along the rim of the tumor, which is usually well per-
fused or surrounded by large blood vessels. For the MR-HIFUY
treated tumors, elevated radioactivity was not restricted to the tumor
rim but more spread over the entire tumor. In our previous work, we
found more than 50% of 111In-TSLs still being present in the blood
circulation after 90 minutes.36 Therefore, it is hard to distinguish
between tumor uptake of TSLs and liposomes circulating in the
blood at this time. However, because the high radioactivity in non-
heated tumors coincides with the vascularized tumor rim, the TSLs
present in the blood circulation are the most likely explanation for
this observation. Although there was no increase in the absolute
amount of radioactivity present in the HIFU-treated tumors after
90 minutes compared with control, the activity was distributed dif-
ferently over the tumor tissue. This suggests a rebalance of perfusion
between the tumor periphery and core due to the increased perfusion
of the heated tumor areas. The radioactivity was measured in a single
slice taken from the tumor center, as well as in the whole tumor
volume. Taking into account that more than 50% of the radiolabeled
TSLs are still present in the blood circulation after 90 minutes, the
absolute amount of radioactivity is heavily affected by the blood
volume distribution in the selected tumor slice. The blood distribu-
tion, as well as tumor heterogeneity in general, also explains the
difference in absolute activities found in the whole tumors as com-
pared with tumor slices. On the other hand, with less than 5% of
111In-TSLs present in the blood after 48 hours, the autoradiography
FIGURE 4. T2-weightedMR image and R1 maps before TSL injection and after each heating period, with HIFU-mediated hyperthermia
(upper row) and control (lower row). No heating was applied for the control tumors; therefore, the R1 maps acquired 15 minutes (first
heating) and 30 minutes (second heating) after TSL injection are shown. On the R1 maps, the tumor is delineated with a red line.
FIGURE 5. Pictures and autoradiography of slices fromHIFU-treated and control tumors, 90minutes and 48 hours after TSL injection.
One typical example is shown per group; the results of all measured tumors (n = 12) are shown in the Supplementary Information
(Supplemental Figure S1, Supplemental Digital Content 1, http://links.lww.com/RLI/A74). The %ID/g was determined by
F-counting. Control tumors showed the highest activity in the rim, whereas the HIFU-treated tumors showed a different activity
distribution. See Supplementary Information for the corresponding activity profiles.
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images at this time point reflect radiolabeled liposomes accumulated
in the tumor. The heated and control tumors after 48 hours showed
an increased %ID/g of TSL in comparison with the autoradiographic
images at 90 minutes. The 111In-TSL accumulation in the MR-
HIFUYtreated tumors was higher in comparison with that in non-
heated tumors, which was not yet observed after 90 minutes. These
results suggest that HIFU-based hyperthermia has caused long-
lasting effects, which enhanced liposomal uptake over a much longer
time period compared with the hyperthermia treatment itself. These
findings are consistent with earlier experiments published by Kong
et al24 showing that hyperthermia increases the extravasation of lipo-
somes because of a further enhanced permeability and retention ef-
fect in tumors. These effects of hyperthermia on extravasation extended
to several hours after administration. As a consequence, doxorubicin
levels in the tumor may further increase beyond the amount observed
directly after intravascular release triggered by hyperthermia due
to further but slow accumulation of drug-filled TSLs that are still
circulating. These results are of general importance to applications
in liposomal drug delivery because both temperature-sensitive and
commercially available nonYtemperature sensitive liposomal drugs
(eg, Doxil, Caelyx) will benefit from the increased extravasation due
to HIFU-mediated hyperthermia.
The intratumoral distribution of doxorubicin for the different
time points and groups was studied using fluorescence microscopy.
At 90 minutes after injection, doxorubicin uptake in HIFU-treated
tumors was observed in cells at a much larger distance from blood
vessels in comparison with the control tumors, where doxorubicin
uptake was visible only in the vicinity of blood vessels. Recently,
Manzoor et al45 showed similar results after electric heating in a
TABLE 1. CV and Amount of 111In in the Tumor Slice and the






HIFU-HT 90 min 0.7 T 0.2 0.29 T 0.01 0.55 T 0.31
Control 90 min 1.1 T 0.2 0.29 T 0.08 0.64 T 0.24
HIFU-HT 48 h 0.6 T 0.1 1.42 T 0.75 4.21 T 1.41
Control 48 h 1.4 T 0.4 0.48 T 0.13 1.99 (n = 1)
FIGURE 6. Histology of HIFU-mediated hyperthermia-treated and control tumor tissue 90minutes after TSL injection. Of each staining,
an overview image of the whole tumor slice as well as a 40 zoom is shown. Shutter times for doxorubicin were 3 seconds (overview)
and 1 second (40 zoom). On NADH-diaphorase staining, viable cells appear blue, whereas nonviable cells would remain colorless.
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window-chamber model; they observed an increase in drug penetra-
tion distance after intravascular release from TSLs. Two days after
TSL injection, the doxorubicin was spread throughout the tumor for
both the control and HIFU-treated groups. In addition, this observa-
tion corresponds with findings from previous studies with non-TSLs,
where the drug initially appeared to be restricted to the perivascular
space, most likely still encapsulated inside the liposome, but spread
throughout the tumor 24 to 48 hours later.46,47 The limited bio-
availability of the drug at early time points because of slow release
from these non-TSLs and the subsequent diffusion-driven distribu-
tion across the tumor may be the underlying reason for the observed
suboptimal antitumor efficacy in the clinic.48Y50 In our study, the
fluorescence intensity was much higher for the HIFU-treated tumors
as opposed to controls, suggesting an increased amount of drug
uptake by the heated tumors. Furthermore, doxorubicin becomes
directly bioavailable to tumor cells after the temperature-triggered
release from the TSLs.
Previously, we have shown that mild hyperthermia of para-
magnetic TSLs containing doxorubicin and [Gd(HPDO3A)(H2O)]
leads to a simultaneous release of the encapsulated molecules. The
change in R1 was found to be proportional to the amount of drug
delivered in 9L gliosarcoma tumors in rats.36 In this study, an in-
crease in the R1 was observed immediately after HIFU treatment in
a rat rhabdomyosarcoma tumor model, whereas no distinct effect
was visible in the control tumor. No further increase in R1 was mea-
sured after the second hyperthermia treatment, indicating that equi-
librium was reached between washout and release of the MRI CA.
Overall, the observed $R1 due to [Gd(HPDO3A)(H2O)] release from
TSLs during HIFU treatment in the rhabdomyosarcoma tumor
model was smaller than the effect observed previously in 9L glio-
sarcoma tumors.36 Histological examination of both tumor models
showed better structured and more homogeneously formed blood
vessels in the rhabdomyosarcoma model in comparison with the 9L
tumor (Supplemental Figure S3, Supplemental Digital Content 3,
FIGURE 7. Histology of HIFU-mediated hyperthermia-treated and control tumor tissue 48 hours after TSL injection. Shutter times for
doxorubicinwere 3 seconds (overview) and 1 second (40 zoom). For the control tumor and area 2 of the hyperthermia-treated tumor,
the doxorubicin signal intensity was very low. Therefore, images were acquired both with the standard shutter time of
1 second and with a longer shutter time of 6 seconds (indicated in the images). The small boxes indicate where the enlarged images
were taken (area 1 and 2). Area 1 shows high signal in the dox channel, as well as in the FITC channel.
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http://links.lww.com/RLI/A76). As expected, the different blood ves-
sel structures also resulted in differences in vessel permeability as
measured by dynamic contrast-enhanced MRI, showing ktrans = 0.05
minj1, kep = 0.26 min
j1, and ve = 0.21 for the rhabdomyosarcoma
tumor and ktrans = 0.25 min
j1, kep = 0.37 min
j1, ve = 0.66 for the 9L
tumor (Supplemental Figure S4, Supplemental Digital Content 4,
http://links.lww.com/RLI/A77). It is important to note that the pharma-
cokinetic properties of the encapsulated agents before release from the
lumen of the TSLs are determined by the liposomal carrier. Upon re-
lease, however, the doxorubicin and [Gd(HPDO3A)(H2O)] will show
different biodistribution profiles and tumor uptake. The high perme-
ability of doxorubicin across different barriers will result in a rapid
distribution in the interstitial space and cellular uptake across the tu-
mor upon its local release.25,45,51,52 On the other hand, [Gd(HPDO3A)
(H2O)] will distribute across the extracellular space,53 and its intratu-
moral concentration is a balance between tumor inflow and washout.
Therefore, the smaller $R1 change observed in the rhabdomyosarcoma
model can most likely be explained by the considerably lower ktrans
and ve in this tumor compared with the 9L tumor. Quantitative mea-
surements of the doxorubicin and gadolinium concentrations and a
comparison with $R1 were not performed in this study because the
tumors were used for histology and autoradiography examinations.
As discussed before, mild hyperthermia can be used to im-
prove liposomal chemotherapy in 2 ways. First, hyperthermia leads to
an increase in vascular permeability and therefore increasing levels of
liposome accumulation, and second, hyperthermia can be used for a
triggered drug release from TSLs.54 In a recent review by Grüll and
Langereis,55 studies on MR-HIFUYinduced delivery from TSLs have
been summarized, reporting a heating-induced 2.3- to 4.9-fold en-
hancement in tumor doxorubicin concentrations at early time points.
This enhancement effect was caused mainly by the intravascular re-
lease of doxorubicin during heating. Any additional drug accumula-
tion due to extravasation and uptake of long circulating TSLs and
subsequent release of doxorubicin was so far not systematically in-
vestigated. Dromi et al56 investigated doxorubicin uptake in tumors
at 24 hours after TSL injection followed by pulsed-HIFU exposures.
They did not observe a difference between HIFU-exposed and un-
treated tumors, but this may be attributed to the relatively short ex-
posure of 2 minutes per pulsed-HIFU raster point. Although quantitative
measurements of doxorubicin concentrations were not performed in our
study, it is quite likely that the measured increase in TSL uptake in heated
tumors over 2 days will lead to a further increase in doxorubicin con-
centrations beyond the level found directly after hyperthermia treatment.
In this study, we observed that the HIFU-treated tumors showed ne-
crotic areas at 48 hours after the treatment, corresponding to the areas
where large amounts of radioactivity were detected. This observation
suggested that the doxorubicin uptake in these areas exceeded the
concentrations necessary for cell necrosis. Because no necrosis was
detected at 90 minutes after the treatment, it can be assumed that the
observed cell death in these tumors was a long-term effect.
In conclusion, MR-HIFU is a promising technology for
hyperthermia-induced drug delivery in oncology. Magnetic resonance
imaging provides spatial guidance during the planning and treatment
as well as accurate temperature feedback to the HIFU transducer.
Hyperthermia induced by HIFU was shown to increase drug release
from TSLs during hyperthermia and to increase uptake of liposomal
FIGURE 8. Pictures, autoradiography, viability NADH staining, and fluorescence signal intensity in the dox channel of all tumors
dissected 48 hours after hyperthermia treatment. The red contour indicates the necrotic area as determined based on the NADH
staining, which is overlayed on the autoradiographic image and on the fluorescence image taken from the same histology slice.
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drug delivery carriers in the period after the hyperthermia. In
addition, MRI allows to image drug release using TSLs encapsulat-
ing MRI CA and doxorubicin. In the hyperthermia group, intravas-
cular release of doxorubicin led to a homogeneous drug coverage of
large areas within the tumor. Moreover, liposome accumulation and
penetration were increased because of the HIFU hyperthermia treat-
ment. These accumulated liposomes will slowly release the drug
throughout the tumor over a longer time period, resulting in even
more bioavailable drug present at the tumor site. Both the intravas-
cular release of doxorubicin and the increased accumulation of
doxorubicin-filled liposomes may have an important contribution to
the therapeutic outcome.
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